Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowBiotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Exton, Pa.-based Adolor will pay $2 million upfront to
Indianapolis-based Eli Lilly, along with future royalties and milestone payments potentially worth $70 million.
Adolor
said it initially intends to develop the drug candidate as a potential opioid bowel-dysfunction treatment and will start clinical
trials in early 2010. The condition normally refers to chronically constipated patients taking opioid pain drugs.
Please enable JavaScript to view this content.